newcleo, the advanced nuclear company developing lead-cooled fast reactors and MOX fuel, is going public via a merger with NewHold Investment Corp. III (Nasdaq: NHIC). The deal values newcleo at about $2.4 billion pre-money and could bring in roughly $429 million before redemptions, but the setup still carries heavy execution, regulatory, and dilution risk.
newcleo, the advanced nuclear company developing lead-cooled fast reactors and MOX fuel, is going public via a merger with NewHold Investment Corp. III (Nasdaq: NHIC). The deal values newcleo at about $2.4 billion pre-money and could bring in roughly $429 million before redemptions, but the setup still carries heavy execution, regulatory, and dilution risk.
Deal at a Glance
SPAC partner: NewHold Investment Corp. III
SPAC ticker (trades now): NHIC
Expected post-merger ticker: NWCL
Implied valuation: $2.4B pre-money equity value
Expected close: H2 2026
Est. first trading date: late Q3 2026 to Q4 2026
Deal status: Announced
Source filing: SEC 425 (2026-06-30)
Company Overview
newcleo is an advanced nuclear company founded in London in 2021 that is building lead-cooled fast reactors (LFRs) and mixed oxide (MOX) nuclear fuel made from reprocessed nuclear materials. The company describes itself as a vertically integrated nuclear technology and services business with revenue streams from license sales, engineering services, EPCM contracts, components and nuclear fuel, plus maintenance and operational support.
The company says it operates in seven countries with a footprint across Europe and the U.S., and it reports 900+ employees, 31 patent families, 16 offices, 3 sites, 3 factories, and 3 qualification/R&D/training centers. It also disclosed $80 million in 2024 revenue, other income and financial income, which is meaningful for a nuclear startup but still far from commercial-scale reactor deployment. The industry backdrop is a push for firm 24/7 power as electricity demand rises, especially from industrial load and data centers, with the company citing roughly 75% growth in U.S. and Europe electricity demand from 2024 to 2040.
The SPAC Deal
newcleo is merging with NewHold Investment Corp. III, which currently trades as NHIC. The merger agreement assigns newcleo a base equity value of US$2.35 billion, and the company and press materials round that to about $2.4 billion pre-money equity value. The investor presentation shows a pro forma enterprise value of $2.374 billion and a pro forma market capitalization of $2.903 billion under no-redemption / full PIPE assumptions.
On the financing side, NHIC had at least $209.22 million in trust at signing, but that amount is explicitly before redemptions and transaction expenses. The deal also includes a $220 million PIPE, bringing headline gross proceeds to as much as $429 million before redemptions. The materials do not name the PIPE investors. The sponsor structure is also not clean: 20% of the sponsor promote is forfeited upfront, the remainder is subject to forfeiture based on delivered capital and price vesting, and founder shares have performance hurdles. NHIC’s IPO included one-half warrant per unit, with each whole warrant exercisable at $11.50, and the merger agreement says the warrants will be terminated or amended into company warrants at closing. That leaves a meaningful dilution overhang for public holders.
The deal was announced on May 27, 2026 and remains announced, not closed. The company expects to complete the transaction in the second half of 2026. If it closes on that timeline, the combined company should start trading shortly after shareholder approval and closing, likely in late Q3 to Q4 2026. The expected post-merger ticker is NWCL, while the SPAC currently trades under NHIC.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The obvious use of proceeds is to fund newcleo’s reactor and fuel commercialization plan, including licensing, engineering, manufacturing, and regulatory work across its LFR and MOX platform. The company says it has already advanced milestones such as the 2MW OTHELLO testbed, safety licensing filings in France, a JV with JAVYS in Slovakia, and a partnership with Oklo for a U.S. advanced fuel manufacturing facility.
The SPAC route also gives newcleo access to a large committed capital package and a public currency without waiting for a traditional IPO market window. It also lets the company present forward-looking commercialization milestones and illustrative revenue streams in its investor materials, though those are explicitly estimates and not guarantees. For a capital-intensive nuclear developer, that combination of speed, sponsor backing, and financing certainty is the main appeal.
Financial Highlights
newcleo disclosed $80 million in 2024 revenue, other income and financial income, but the materials reviewed do not provide a full audited income statement or a clean net loss figure. That means investors should treat the company as still early-stage despite the revenue line, especially because management says it remains in a pre-industrial phase and large-scale commercial revenue will not arrive until reactors are online.
On liquidity, newcleo says it has raised more than $780 million of private funds since founding. The deal is expected to deliver about $374 million to newcleo’s balance sheet assuming no redemptions, after fees and expenses, but that is a projected post-close outcome rather than cash already in hand. The deck also includes forward projections and regulatory timing targets, including first NRC applications in 2026 and 2027 for certain projects, but those are estimates only and may not be realized.
Risk Factors
The biggest de-SPAC risk is that trust cash can walk. NHIC’s trust was about $209 million at signing, but that figure is before redemptions, and the deck’s headline funding math assumes no redemptions. If shareholders redeem heavily, the cash delivered at close could fall materially, which would pressure the balance sheet and increase reliance on the PIPE and other financing. The deal also carries the usual SPAC dilution stack: sponsor promote, PIPE shares, and warrants all reduce the economics for public holders.
The operating risk is just as important. newcleo is still pre-industrial, so commercial scale revenue depends on reactor deployment, fuel manufacturing, and licensing success. Regulatory approvals from bodies such as the NRC, ASNR, and UJD are still pending or in process. The company also flags cost and market-adoption risk: MOX fuel may not be cost competitive, and the market for recycled nuclear fuel may be smaller or slower to develop than expected. In a capital-intensive nuclear buildout, any delay can push out cash needs and compress the path to value creation.
Comparable Public Companies
newcleo points investors toward a peer set that includes Oklo (OKLO), NuScale Power (SMR), and X-energy, with BWX Technologies (BWXT) also useful as a public nuclear hardware/services reference. Among those, OKLO and SMR are the closest public comps because they sit in the advanced nuclear / SMR conversation and trade on commercialization expectations rather than near-term earnings.
The company’s own materials say it compares at a substantial discount to these peers, but the excerpts reviewed do not provide a formal multiple table. In broad terms, the public comp set has been driven more by policy, permitting, and long-duration growth narratives than by current profits, which is exactly why investors should focus on whether newcleo can convert its technology story into licensed, financed, and buildable projects. The comp list for cross-checking is OKLO, SMR, and BWXT.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
This is a high-upside, high-uncertainty de-SPAC. The setup favors investors who want exposure to advanced nuclear optionality, but the deal still has to clear the usual SPAC hurdles: redemptions, shareholder approval, and final close. The key numbers to watch are the trust balance after redemptions, the PIPE certainty, and how much dilution survives from sponsor promote and warrants.
Why this matters now is simple: newcleo is trying to move from a private nuclear developer with real milestones into a public company with more capital and a public ticker. If the transaction closes in the second half of 2026, the market will quickly reprice the story around execution, not just technology. Shareholders should watch whether the company can preserve enough cash at close to fund the next phase without leaning too hard on future dilution.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
